Cohen M B, Giannella R A, Losonsky G A, Lang D R, Parker S, Hawkins J A, Gunther C, Schiff G A
Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
Infect Immun. 1999 Dec;67(12):6346-9. doi: 10.1128/IAI.67.12.6346-6349.1999.
Until recently, all epidemic strains of Vibrio cholerae were of the O1 serotype. Current epidemics have also been caused by a new serotype, Vibrio cholerae O139. Although the pathogenesis and clinical features of O139 cholera are similar to those of O1 cholera, immunity to serotype O1 does not confer immunity to serotype O139. Therefore, prior to beginning vaccine efficacy studies, we sought to validate the use of a large standardized frozen inoculum of virulent V. cholerae O139 4260B for use in a human volunteer challenge model. Healthy volunteers (n = 25) were recruited for an Internal Review Board-approved inpatient dose-escalation challenge. Our goal was to identify a dose at which the cholera attack rate and the geometric mean purge were sufficient for determining vaccine efficacy against moderate and severe disease. At a dose of 10(5) CFU, 8 of 10 volunteers experienced purging and had a positive stool culture for V. cholerae. However, at this dose, the geometric mean stool volume of 2,175 g was insufficient by study criteria. At a dose of 10(6) CFU, 14 of 15 volunteers experienced purging, with a geometric mean stool volume of 5,621 g. Disease severity was significantly greater in volunteers with blood group O than those with non-O blood types (10,353 g versus 3,555 g, P < 0.001). Following challenge, all volunteers demonstrated a significant rise in antitoxin antibodies but the serum vibriocidal titer was attenuated compared to that seen after challenge with an O1 strain. This model provides a reproducible illness of sufficient severity for testing the efficacies of new O139 or combined O1-O139 vaccines.
直到最近,所有霍乱弧菌的流行菌株都属于O1血清型。当前的疫情也由一种新的血清型霍乱弧菌O139引起。尽管O139霍乱的发病机制和临床特征与O1霍乱相似,但对O1血清型的免疫力并不能赋予对O139血清型的免疫力。因此,在开始疫苗效力研究之前,我们试图验证使用大量标准化的强毒霍乱弧菌O139 4260B冷冻接种物用于人类志愿者攻毒模型的可行性。招募了健康志愿者(n = 25)进行经内部审查委员会批准的住院剂量递增攻毒试验。我们的目标是确定一个剂量,在此剂量下霍乱发病率和几何平均腹泻量足以确定针对中度和重度疾病的疫苗效力。在10⁵CFU的剂量下,10名志愿者中有8名出现腹泻,且粪便霍乱弧菌培养呈阳性。然而,根据研究标准,在此剂量下2175克的几何平均粪便量是不够的。在10⁶CFU的剂量下,15名志愿者中有14名出现腹泻,几何平均粪便量为5621克。O血型志愿者的疾病严重程度明显高于非O血型志愿者(分别为10353克和3555克,P < 0.001)。攻毒后,所有志愿者的抗毒素抗体均显著升高,但与用O1菌株攻毒后相比,血清杀菌效价有所降低。该模型为测试新型O139或联合O1 - O139疫苗的效力提供了一种具有可重复性且严重程度足够的疾病模型。